GALECTIN THERAPEUTICS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$20.1M | -$42.4M | -$38.1M | -$38.4M | -$30.2M |
| Operating expenses | $20.1M | $42.4M | $38.1M | $38.4M | $30.2M |
| Cash from operations | -$23.9M | -$41.8M | -$33.0M | -$31.1M | -$24.3M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $19.5M | $17.5M | $28.2M | $21.3M | $41.8M |
| Total liabilities | $145.7M | $120.6M | $88.4M | $53.5M | $39.2M |
Shares outstanding 65.9M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.